Inventor
GOUBLE AGNES
FR13 patents
⚠️ This page may combine multiple inventors who share the name “GOUBLE AGNES”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELLECTIS
12 patentsUS7842489B2Nov 30, 2010
Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
CELLECTIS63 citations95
US10426795B2Oct 1, 2019
Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells
CELLECTIS8 citations92
US10286007B2May 14, 2019
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS12 citations92
US11274316B2Mar 15, 2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS2 citations83
US10517896B2Dec 31, 2019
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS2 citations83
US10363270B2Jul 30, 2019
Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapy
CELLECTIS6 citations83
US12577581B2Mar 17, 2026
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS0 citations72
US11891614B2Feb 6, 2024
Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
CELLECTIS1 citations72
US11414674B2Aug 16, 2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells
CELLECTIS0 citations72
US11304975B2Apr 19, 2022
Methods for engineering allogeneic and highly active t cell for immunotherapy
CELLECTIS4 citations72
US11311575B2Apr 26, 2022
Methods for engineering highly active T cell for immunotherapy
CELLECTIS1 citations62
US11767512B2Sep 26, 2023
Sequence specific reagents targeting CCR5 in primary hematopoietic cells
CELLECTIS0 citations57